Early warning: PSA testing can predict advanced prostate cancerFebruary 15, 2008Researchers who showed that a single prostate specific antigen (PSA) test at age 50 or under could predict the presence of prostate cancer up to 25 years later, (regardless of clinical significance) have now found that a single PSA can be used to predict advanced prostate cancer. The findings, published in the online open access journal BMC Medicine, should help physicians identify which men would benefit from intensive screening. More men die with prostate cancer than from it and in many cases the quality or length of their lives are not affected. However, advanced prostate cancer has serious consequences, including death. Researchers from Memorial Sloan-Kettering Cancer Center, New York and Lund University, Sweden set out to investigate the ability of a single PSA test to predict a diagnosis of advanced prostate cancer in later life. Advanced cancer was defined as one where the cancer had spread locally beyond the prostate or to other parts of the body at the time of diagnosis.
The team studied blood samples collected between 1974 and 1986 as part of a large population-based study of middle-aged men. The study cohort included 161 men who had been diagnosed with advanced prostate cancer by 1999 and men of a similar age who had not developed cancer by that time. The results showed that the total PSA level was an accurate predictor of advanced cancer diagnosis in later life. The majority (66%) of advanced cancers were seen in men whose PSA levels were in the top 20% (total PSA > 0.9 ng/ml). The median time from blood test to cancer diagnosis was 17 years. The authors write: "A single PSA test taken at or before age 50 is a very strong predictor of advanced prostate cancer diagnosed up to 25 years later. This suggests the possibility of using an early PSA test to risk stratify patients so that men at highest risk are the focus of the most intensive screening efforts." Targeting screening could allow physicians to intervene when the cancer is at an early stage and still curable. It could also reduce 'overdiagnosis' and unnecessary treatment in men with benign tumours. BioMed Central | |||||||||||||||||||||
|
Related Prostate Cancer Current Events and Prostate Cancer News Articles New Catheter-less Technique May Ease the Pain and Discomfort of Prostate Cancer Recovery To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. Racial disparities decline for cancer in Missouri Cancer death rates in the United States are highest among African Americans, but a new report shows that in Missouri the disparity in cancer incidence and death between African Americans and whites is declining. OHSU Cancer Institute researchers study breathing during radiation Oregon Health & Science University researchers have determined exactly how much breathing affects prostate movement during radiation treatment. Hormone therapy before radiation seed implants for prostate cancer Men over 70 years of age with early-stage prostate cancer have 20 percent higher mortality if they are treated first with hormone therapy before being treated with radiation seed implants (brachytherapy), compared to men who are treated with brachytherapy alone. Newly found gene variants account for kidney diseases among African-Americans For the first time, researchers have identified variations in a single gene that are strongly associated with kidney diseases disproportionately affecting African-Americans. This work was conducted by researchers at the National Institutes of Health (NIH) and by NIH-funded investigators at the Johns Hopkins University. Common painkillers lower levels of prostate cancer biomarker Common painkillers like aspirin and ibuprofen appear to lower a man's PSA level, the blood biomarker widely used by physicians to help gauge whether a man is at risk of prostate cancer. Anti-inflammatory drugs may mask prostate cancer marker Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, may reduce serum levels of the prostate biomarker, PSA (prostate specific antigen), and hence may alter the detection of prostate cancer in individuals who take these medications. Too much calcium in blood may increase risk of fatal prostate cancer Men who have too much calcium in their bloodstreams may have an increased risk of fatal prostate cancer, according to a new analysis from Wake Forest University School of Medicine and the University of Wisconsin. Height linked to risk of prostate cancer development and progression A man's height is a modest marker for risk of prostate cancer development, but is more strongly linked to progression of the cancer, say British researchers who conducted their own study on the connection and also reviewed 58 published studies. Health risk behaviors associated with lower prostate specific antigen awareness According to a study conducted at Columbia University Mailman School of Public Health, health risk behaviors such as smoking and obesity are associated with lower awareness of the Prostate Specific Antigen (PSA), which could lead to a lower likelihood of undergoing actual prostate cancer screening. More Prostate Cancer Current Events and Prostate Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||